DBT approves funding for 3 companies to develop COVID-19 vaccine
Category: #health  By Saipriya Iyer  Date: 2020-04-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

DBT approves funding for 3 companies to develop COVID-19 vaccine

The Department of Biotechnology (DBT) in India has reportedly short-listed three companies and approves the funding for these companies to develop a COVID-19 vaccine. Additionally, it has received 13 funding proposals for therapeutics, diagnostics, and other interventions intending to fight the deadly coronavirus pandemic.

The DBT has stated that a multifaceted approach has been adopted by the vaccine companies to utilize various platforms. It also helped fast track several stages of vaccine development through a research consortium. This consortium has been funded by the National Biopharma Mission, which is an initiative launched in 2017, to support vaccines and drugs development.

The Biotechnology Industry Research Assistance Council and the Department of Biotechnology had invited applications on the Research Consortium of the COVID-19 disease. The DBT has reportedly stated that 500 applicants from industry and academia have been received in the first phase of the study, which ended on 30th March.

Additionally, 16 proposals of the vaccine candidates, therapeutics, diagnostics, devices, & other interventions have been taken under consideration for delivering the funding support. The DBT also stated that the multi-tiered review process is currently happening to further aid the development of the COVID-19 drugs and vaccines.

Development of a novel vaccine candidate and repurposing of the existing vaccine companies to give immediate attention to high-risk groups have been considered as important criteria for proposal selection.

To advance the DNA Vaccine development for use against the SARS-CoV-2, funding support has been recommended to Cadila Healthcare Ltd. Funding has also been recommended for Bharat Biotech International Ltd. to develop vaccine candidate that utilizes the inactivated rabies vector platform. Additionally, SIIPL (Serum Institute of India Private Limited) will also be supported in its Phase III human clinical trial of the recombinant BCG vaccine study which was planned to be conducted among high-risk population.

Source credit:

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dbt-approves-funding-for-three-companies-for-developing-covid-19-vaccine/articleshow/75247163.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...

Omada enters $30M acquisition deal with digital health company Physera
Omada enters $30M acquisition deal with digital health company Physera
By Saipriya Iyer

Omada Health, which has raised nearly $57 million in funding, has reportedly acquired a digital health company, Physera. It provides remote physical therapy to its customers.

The co...